On September 9, EVEREST MED fell 5.02% in regular trading, trading at approximately HKD 31.34/share, with turnover of approximately HKD 92.46 million. The decline came as the stock gave back gains from the prior session, when shares had surged 5.56% following a key regulatory milestone.

On September 3, EVEREST MED announced that Xingbituo (etripamil nasal spray) received approval from China's NMPA for the treatment of acute episodes of paroxysmal supraventricular tachycardia (PSVT) in adults — the first and only innovative therapy approved for this indication in over 30 years. The approval, based on two Phase III clinical studies, also triggered a USD 2 million milestone payment to Milestone Pharmaceuticals under the licensing agreement, which carries total potential milestones of up to USD 98 million and royalties of up to 18% for the Greater China region. The stock's reversal reflects a typical pattern of profit-taking after a positive catalyst is fully absorbed.

Broader weakness in the biotechnology sector further weighed on shares, with peers BEONE MEDICINES down 1.97% and CANSINOBIO down 2.78%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)